Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
>>> For the latest QIDP list, please click HERE <<< Since our last QIDP blog from April 8, 2015, several new drugs have made the list which now includes 41 compounds. Below a table which includes compound, sponsor and development stage (Phase). It also indicates whether a drug has been the topic of a Continue reading QIDP Drugs – 4th Edition
PLEASE SHARE YOUR OPINION AND VOTE BELOW On May 8th, 2015 moxifloxacin/Avelox was approved for treatment of inhalational plague.[1] We learn that the approval followed the ‘animal rule’ process, and that treatment with moxifloxacin was 100% effective in the African Green Monkey (AGM) model of lung infection. By contrast, 0% of Continue reading Why Moxifloxacin’s Approval for Plague Is So Disturbing
Looking across the Northern border it is clear that CDC Guidelines are not universally followed even in North America. Public Health Canada still recommends cefixime for uncomplicated gonorrhea (GC), albeit at the high single oral dose of 800 mg [1]. In the US, CDC has opted for combination treatment with ceftriaxone Continue reading Treating GC in the Face of Dwindling Antibiotic Options – (1)